Peregrine Pharmaceuticals has received a European patent for its In-Line labeling technology, used to link biological agents to labels for diagnostic and therapeutic applications.
The technology was developed for the production of radiolabeled anticancer antibodies, but is applicable to other agents as well, according to the Tustin, CA-based vendor. A study published in the July 2009 issue of the Journal of Nuclear Medicine found that In-line labeling can reduce the complexity and cost of producing radiolabeled cancer drugs, Peregrine said.
Related Reading
Peregrine reports healthy Q3 revenue, March 13, 2009
Peregrine mourns loss of chairman, December 11, 2008
Peregrine gains more time for compliance, October 23, 2008
Peregrine posts Q1 2009 results, September 10, 2008
Peregrine establishes Chinese subsidiary, sues CTL, January 12, 2007
Copyright © 2009 AuntMinnie.com
